Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Trial ID or NCT#

NCT01844765

Status

not recruiting iconNOT RECRUITING

Purpose

To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to \<18 years).

Official Title

A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib

Eligibility Criteria

Ages Eligible for Study: 1 Year to 17 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib* Karnofsky ≥ 50% for patients \> 10 years of age and Lansky ≥ 50 for patients ≤ 10 years of age* Adequate renal, hepatic and pancreatic function* Potassium, magnesium, phosphorus and total calcium values ≥ LLN (lower limit of normal)* Written informed consent
    1. Key
Exclusion Criteria:
  1. * Treatment with strong CYP3A4 inhibitors or inducers* Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval* Acute or chronic liver, pancreatic or severe renal disease* History of pancreatitis or chronic pancreatitis.* Impaired cardiac function* No evidence of active graft vs host and \<3mo since Stem Cell Transplant* Total body irradiation (TBI) or craniospinal radiation therapy \<6months* Hypersensitivity to the active ingredient or any of the excipients including lactose.* the criteria regarding pregnancy and contraception* Active or systemic bacterial, fungal, or viral infection* known Hepatitis B, Hepatitis C, or HIV infection
View All Criteria
Show Less

Investigator(s)

Kara Davis

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov